reason report
stabl enough portfolio challeng mount
mp pt
bottom line yesterday kept streak strong result
large-cap biotech compani beat consensu estim
revenu earn also exceed
above-consensu forecast despit price pressur domest
intern market still manag keep total revenu
grow total revenu
consensu estim
one-tim item contribut approxim result
oper revenu grew adjust item
like larg cap compani pledg vow
abstin price increas price contribut year
year top line perform oper margin
expect share repurchas quarter
contribut posit pro forma earn growth beat
consensu estim despit
perform medium long term growth outlook
compani uncertain given immin challeng biosimilar
launch neulasta epogen eros
aranesp increas competit challeng enbrel
unclear us whether launch aimovig support
gener free good program launch continu growth
xgeva prolia hand nich product off-set
eros compar peer pharma biotech compani amgen
late stage pipelin remain rel lean departur two
senior commerci execut reassur investor
compani near term outlook base quarter result
manag comment make modest chang
revenu forecast year increas ep
estim year base lower share count
chang chang peer compani multipl increas price
target reiter market perform rate
net debt total capit
price-to-earnings lt ep growth
averag dcf price-to-earnings p/sale
compani inform leerink partner llc research
revenu million dilut non-gaap ep
pleas refer page import disclosur price chart analyst certif
price target inc stock rate market perform
one first gener pioneer biopharmaceut industri succeed
basi build three massiv revenu pillar legaci product era three
product franchis epo epogen aranesp gcsf neulasta enbrel
face array brand gener competitor mean associ
revenu total like steadili declin offset outlook
number recent develop acquir product growth profit potenti
view unlik match legaci brand least mani year amgen
manag respond challeng restructur compani expens base
initi dividend lever compani balanc sheet cash trap off-shore
gener make legaci product compar peer regard
defens stock also one lack explos upsid potenti typic associ
breakthrough rapidli grow biotherapeut stock
total revenu grow slowli price pressur affect mani product total
revenu consensu estim
product sale grew yoy compar weak result howev
total revenu beat came revenu includ substanti mileston
payment partner novarti aimovig approv price contribut growth
volum top line beat mainli driven neulasta vs consensu
vs lp enjoy final quarter unbiosimilar- sale prolia vs
consensu vs lp sensipar vs consensu vs lp
similarli benefit appar posit price ahead immin gener launch
enbrel sale came consensu estim
yoy declin enbrel sale partial result signific inventori build
underli volum enbrel declin perform product
larg line street forecast compar us sale flat yoy
intern sale grew volum growth among mani product unit
growth outpac sale growth reflect trend slightli declin price also
disclos confer call cancel previous plan price increas
juli follow public drug price blueprint administr
oper margin disciplin favor tax rate share repurchas propel ep beat
gross margin exceed estim line prior period
expens essenti flat yoy sg expens increas year ago
repres total product sale sg appear grow faster revenu
appear compani increas commerci invest competit
intens payer scrutini product increas also launch aimovig
requir up-front invest overal oper margin stay strong although
manag caution oper margin would lower due time
expens tax rate quarter non-gaap ep came
repres growth yoy repurchas share common stock total
cost quarter reduc dilut share count compar
end compani still remain stock repurchas author
plan repurchas anoth stock year
revenu ep guidanc rais also rais total revenu guidanc
full year previous guidanc rais due
perform date still reflect compani concern biosimilar competit
neulasta aranesp rang potenti sensipar gener competit outcom
compani maintain guidanc tax rate rang basi
non- basi guidanc ep increas
guidanc non-gaap ep increas
compani expect capit expenditur year
approxim consist previou guidanc
key execut retir success alreadi place togeth earn
result announc retir two execut offic success plan
posit sean harper md long-standing head anthoni hooper
current execut vice presid global commerci oper retir year follow
transit period dr harper succeed david rees md current senior
vice presid translat scienc oncolog extens clinic
translat research experi academia join murdo gordon
week announc departur posit chief commerci offic bristol-my
squibb join septemb execut vice presid global commerci
free aimovig help maxim first-to-market advantag migrain first-
in-class cgrp receptor antibodi amgen aimovig approv fda may
expect analyst investor potenti growth driver unsurprisingli launch
experi aimovig becam major focu call accord compani
first two month launch patient receiv free drug secur
insur coverag patient rapidli convert patient
pay commerci custom expect new patient flow reach steadi state next
week bolu patient pass patient access hub set partner
novarti accord media report patient commerci insur could get
month free drug negoti coverag payer result
expect aimovig gener meaning revenu near term revenu disclos
quarter especi payer incentiv delay coverag take advantag
biosimilar eros neulasta underway threat recent approv
biosimilar version neulasta fulphila appear result
activ market product probabl neulasta last quarter stabl sale
mylan fulphila price discount neulasta list price despit amgen
promot neulasta onpro kit physician payer either demand similar discount
switch disclos current neulasta sale us
onpro kit recent launch onpro germani uk netherland poland
ireland austria uptak onpro strong also show sign slow
adopt share expect leverag advantag onpro reduc
ineffici hospit save time oncologists/nurses/pharmacist howev
uncertain much conveni factor explain adopt much adopt
attribut contract price tactic
pipelin laden earli stage molecul catalyst pipelin
signific gap market product typic broad portfolio earli stage asset
end year data expect phase ii poc studi
antibodi migrain prevent phase trial bcma bite
bite none seem like move stock affect investor sentiment
expect bcma antibody-drug conjug de-priorit due
less impress profil meaning event later year probabl
fda accept bla even re-submit earlier month
call manag sound confid prospect approv
acknowledg safeti signal previous identifi remain unchang re-
adjud opinion safeti signal occur chanc follow
aimovig tri expand footprint neurosci two larg studi
bace inhibitor pre-symptomat cognit normal subject risk alzheim
diseas carri least one allel given tendenc carrier develop
aggress alzheim diseas earlier may take logic approach
test activ medicin unfortun trial even plan enrol
schedul read
modest model updat above-consensu forecast pt base quarter
result manag comment make modest chang revenu forecast /-
year increas ep estim year base lower share count
revenu forecast recent consensu line
consensu ep forecast consensu
chang chang peer compani multipl increas price target
reiter market perform rate stock
price target inc base averag three approach
believ reason basi valu stock today approach simpl price
earn multipl larg cap us eu larg cap biopharma stock sni
rhhbi gsk nv price sale multipl larg cap biotechnolog pharma
compani novo discount cash flow dcf use rel multipl
larg cap biopharma compani ep appli ep
estim give one year futur valu use establish larg cap
futur revenu multipl sale appli revenu forecast amgen
give futur valu final dcf valuat base current
outlook compani exist product probability-weight revenu contribut
late stage pipelin program discount compani wacc give
fair valu today averag three approach give price target
risk view outlook valuat includ major chang label
price reimburs coverag compani legaci product failur
compani growth portfolio achiev futur sale forecast risk includ develop
delay disappoint earlier stage pipelin asset earlier signific eros
compani legaci product biosimilar innov competit shortfal
compani effort improv oper margin would also materi affect outlook
valuat would larg dilut acquisit therapeut area platform
million
corp partner revenue incl royalti
po probabl success fda approv
leerink partner research compani file
million
sale
total expens exclud revenue sharing/incl sg
 total revenu
sg total revenu excl profit share
profit share total revenu
leerink partner research compani file
analysi stock price leerink target
method model larg cap healthcar growth stock ep multipl
ep appli amgen ep
leerink updat ep estim
current averag ep multipl consensu ep
compar slow grow us eu larg cap biopharma
impli target price ep
revenu multipl appli leerink revenu forecast
leerink updat revenu estim
current averag larg cap biopharma multipl revenu
impli valu fy revenu
impli target price ep use us pharma compar
method dcf adjust debt declin flow
stabl termin cash flow growth discount
present valu flow termin valu
averag method
leerink partner research compani file factset
